Ramm Pharma (TSE:RAMM)
:RAMM
Want to see TSE:RAMM full AI Analyst Report?
RAMM Stock Chart & Stats
C$0.06
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.06
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.25
Previous CloseN/A
Volume0.00
Average Volume (3M)118.29K
Market Cap
C$1.79M
Enterprise ValueC$866.77K
Total Cash (Recent Filing)C$985.37K
Total Debt (Recent Filing)C$61.30K
Price to Earnings (P/E)―
Beta-2.36
Next Earnings
Jun 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding119,389,320
10 Day Avg. Volume262,784
30 Day Avg. Volume118,288
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.53
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Conservative Capital StructureExtremely low debt reduces interest burden and financial distress risk, giving management durable flexibility to fund operations, R&D, or restructurings over the next several months. This conservatism helps preserve optionality while the company works to stabilise operations.
Improving Cash Outflow Trend Versus Prior YearsA narrowing cash burn trajectory signals that operating performance or cost controls are beginning to take hold. If sustained, this trend lowers future external funding needs and increases the chance of reaching cash‑flow breakeven within a multi-month horizon.
Recent EPS Growth MetricPositive EPS growth indicates improvement in per‑share profitability compared with prior periods despite losses. Persisting this trend would reflect operational progress, helping to reduce losses and support longer‑term recovery in earnings power.
Bears Say
Sharp Revenue Decline And Persistent Deep LossesSustained steep revenue declines and extremely negative margins show the business is not yet generating sufficient scale to cover fixed costs. Over 2–6 months this raises the risk that losses continue absent meaningful revenue recovery or structural cost reductions.
Ongoing Negative Operating And Free Cash FlowContinued negative OCF and FCF indicate the company is not self-funding operations and remains dependent on external capital. Persistent cash burn can force dilution or constrain investment in product development and commercialization over the medium term.
Eroded Equity And Very Poor ROESevere equity erosion and deeply negative ROE reflect cumulative losses that limit balance sheet resilience. A weakened equity base reduces the cushion for shocks and heightens the need for capital raises, increasing execution risk over coming months.
Ramm Pharma News
RAMM FAQ
What was Ramm Pharma’s price range in the past 12 months?
Ramm Pharma lowest stock price was C$0.01 and its highest was C$0.25 in the past 12 months.
What is Ramm Pharma’s market cap?
Ramm Pharma’s market cap is C$1.79M.
When is Ramm Pharma’s upcoming earnings report date?
Ramm Pharma’s upcoming earnings report date is Jun 30, 2026 which is in 62 days.
How were Ramm Pharma’s earnings last quarter?
Currently, no data Available
Is Ramm Pharma overvalued?
According to Wall Street analysts Ramm Pharma’s price is currently Overvalued.
Does Ramm Pharma pay dividends?
Ramm Pharma does not currently pay dividends.
What is Ramm Pharma’s EPS estimate?
Ramm Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ramm Pharma have?
Ramm Pharma has 119,389,320 shares outstanding.
What happened to Ramm Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ramm Pharma?
Currently, no hedge funds are holding shares in TSE:RAMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ramm Pharma
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---